295 related articles for article (PubMed ID: 27480113)
21. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
Cheng S; Ma J; Guo A; Lu P; Leonard JP; Coleman M; Liu M; Buggy JJ; Furman RR; Wang YL
Leukemia; 2014 Mar; 28(3):649-57. PubMed ID: 24270740
[TBL] [Abstract][Full Text] [Related]
22. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
Marquez ME; Hernández-Uzcátegui O; Cornejo A; Vargas P; Da Costa O
Br J Haematol; 2015 Apr; 169(2):211-8. PubMed ID: 25612644
[TBL] [Abstract][Full Text] [Related]
23. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia.
Chen SS; Chang BY; Chang S; Tong T; Ham S; Sherry B; Burger JA; Rai KR; Chiorazzi N
Leukemia; 2016 Apr; 30(4):833-43. PubMed ID: 26582643
[TBL] [Abstract][Full Text] [Related]
24. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
de Rooij MF; Kuil A; Geest CR; Eldering E; Chang BY; Buggy JJ; Pals ST; Spaargaren M
Blood; 2012 Mar; 119(11):2590-4. PubMed ID: 22279054
[TBL] [Abstract][Full Text] [Related]
25. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.
Burger JA; Tsukada N; Burger M; Zvaifler NJ; Dell'Aquila M; Kipps TJ
Blood; 2000 Oct; 96(8):2655-63. PubMed ID: 11023495
[TBL] [Abstract][Full Text] [Related]
26. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
[TBL] [Abstract][Full Text] [Related]
27. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
[TBL] [Abstract][Full Text] [Related]
28. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Morabito F; Gentile M; Seymour JF; Polliack A
Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
[TBL] [Abstract][Full Text] [Related]
29. p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes.
Patrussi L; Capitani N; Cattaneo F; Manganaro N; Gamberucci A; Frezzato F; Martini V; Visentin A; Pelicci PG; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Oncogene; 2018 Mar; 37(11):1534-1550. PubMed ID: 29326436
[TBL] [Abstract][Full Text] [Related]
30. CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.
Ganghammer S; Hutterer E; Hinterseer E; Brachtl G; Asslaber D; Krenn PW; Girbl T; Berghammer P; Geisberger R; Egle A; Zucchetto A; Kruschinski A; Gattei V; Chigaev A; Greil R; Hartmann TN
Oncotarget; 2015 May; 6(14):12048-60. PubMed ID: 25895128
[TBL] [Abstract][Full Text] [Related]
31. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
[TBL] [Abstract][Full Text] [Related]
32. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.
Herman SE; Mustafa RZ; Gyamfi JA; Pittaluga S; Chang S; Chang B; Farooqui M; Wiestner A
Blood; 2014 May; 123(21):3286-95. PubMed ID: 24659631
[TBL] [Abstract][Full Text] [Related]
34. Ibrutinib: a paradigm shift in management of CLL.
Badar T; Burger JA; Wierda WG; O'Brien S
Expert Rev Hematol; 2014 Dec; 7(6):705-17. PubMed ID: 25387837
[TBL] [Abstract][Full Text] [Related]
35. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
[TBL] [Abstract][Full Text] [Related]
36. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
[TBL] [Abstract][Full Text] [Related]
37. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.
Stamatopoulos B; Meuleman N; De Bruyn C; Pieters K; Mineur P; Le Roy C; Saint-Georges S; Varin-Blank N; Cymbalista F; Bron D; Lagneaux L
Haematologica; 2012 Apr; 97(4):608-15. PubMed ID: 22058221
[TBL] [Abstract][Full Text] [Related]
38. Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis.
O'Hayre M; Salanga CL; Kipps TJ; Messmer D; Dorrestein PC; Handel TM
PLoS One; 2010 Jul; 5(7):e11716. PubMed ID: 20661426
[TBL] [Abstract][Full Text] [Related]
39. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.
Kashyap MK; Kumar D; Jones H; Amaya-Chanaga CI; Choi MY; Melo-Cardenas J; Ale-Ali A; Kuhne MR; Sabbatini P; Cohen LJ; Shelat SG; Rassenti LZ; Kipps TJ; Cardarelli PM; Castro JE
Oncotarget; 2016 Jan; 7(3):2809-22. PubMed ID: 26646452
[TBL] [Abstract][Full Text] [Related]
40. Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML.
Zaitseva L; Murray MY; Shafat MS; Lawes MJ; MacEwan DJ; Bowles KM; Rushworth SA
Oncotarget; 2014 Oct; 5(20):9930-8. PubMed ID: 25294819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
